



Ifw

PATENT
ATTORNEY DOCKET NO. 01948/088004

Certificate of Mailing: Date of Deposit: March 21, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathy Kirby
Printed name of person mailing correspondence

Kathy Kirby
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Karumanchi et al	Art Unit:	1646
Serial No.:	10/624,809	Examiner:	Dong Jiang
Filed:	July 21, 2003	Customer No.:	21559
Title:	METHODS OF DIAGNOSING AND TREATING PRE-ECLAMPSIA OR ECLAMPSIA		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception U.S. patents and U.S. patent application publications. A copy of a search report from a related international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

Applicants note that an Information Disclosure Statement and a Form PTO-1449 were filed in this case on February 7, 2005, April 25, 2005, and December 21, 2005. Applicants have not yet received initialed copies of the Forms PTO-1449 and request initialed copies of the Forms PTO-1449.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Date: March 21, 2005 
Respectfully submitted,
Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 01948/088004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/624,809
		Applicant Karumanchi et al
		Filing Date July 21, 2003
		Group 1646
		IDS Filed March 21, 2006
(37 C.F.R. § 1.98(b))		

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	2003/0144298	July 31, 2003	Curwen et al.			
	2004/0038305	February 26, 2004	Poston et al.			
	2005/0025762	February 3, 2005	Karumanchi et al.			
	2005/0148040	July 7, 2005	Thadhani et al.			
	2005/0170444	August 4, 2005	Karumanchi et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Helske et al., "Expression of Vascular Endothelial Growth Factor Receptors 1, 2 and 3 in Placentas From Normal And Complicated Pregnancies," <i>Mol. Hum. Reprod.</i> 7: 205-210 (2001).					
	Levine et al., "Circulating Angiogenic Factors and the Risk Of Preeclampsia," <i>N. Engl. J. Med.</i> 350: 672-683 (2004).					
	Levine et al., "Urinary Placental Growth Factor and Risk of Preeclampsia," <i>JAMA</i> 293: 77-85 (2005).					
	Livingston et al., "Placenta Growth Factor is not an Early Marker For the Development of Severe Preeclampsia," <i>Am. J. Obstet. Gynecol.</i> 184: 1218- 1220 (2001).					
	Livingston et al., "Reductions of Vascular Endothelial Growth Factor and Placental Growth Factor Concentrations in Severe Preeclampsia," <i>Am. J. Obstet. Gynecol.</i> 183: 1554-1557 (2000).					
	Thadhani et al., "First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia," <i>J. Clin. Endocrinol. Metab.</i> 89: 770-775 (2004).					
	International Search Report Application Number PCT/US05/03884					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	